Bringing multi-targeted, first-in-class-to-a-cancer therapies to patients with cancer
Each product candidate is a novel combination and dosing regimen of two generic drugs with established safety profiles. The constituent drugs and dosing regimens are selected based on a four step screening process that uses published literature and expert knowledge to rank each component drug based on its:
Strength of published evidence of efficacy in human cancer studies,
Targeting of known yet undrugged pathophysiology of a cancer and its treatment,
Targeting of known yet undrugged mechanisms of a cancer and its treatment,
Potential to work synergistically to create a first-in-class-to-a-cancer drug combination.
The top ranked investigational combination is evaluted in FDA-sanctioned Phase 2 and Phase 3 studies as an adjunct therapy with approved anti-cancer drug. Because the investigational combination is comprised of two generic drugs, patients can gain access to the new therapy with prescriptions for the generic drugs as soon as positive clinical results are published and treatment guidelines are revised.
In addition, Vicus will seek FDA approval of a fixed-dose-combination of the generic drug components to improve ease-of-use, to increase adherence and to reduce patient's co-pay requirements compared to usage of the generic drug components .